Longitudinal Study of Catecholamine Metabolism in Periodic Catatonia

  • S. Takahashi
  • L. R. Gjessing


Biochemical changes accompanying the clinical cycle in periodic catatonia have been studied in this laboratory since 1927. Gjessing first suggested that cyclic variation in thyroid function might be involved in the clinical symptomatology of the illness. Clinical observations of a stuporous patient revealed many signs of adrenal activation. The symptoms during the switch from interval to psychotic phase were similar to those seen after an epinephrine injection. Further extensive studies of phenolic amines and phenolic acids have confirmed the overactivity of the sympathetic nervous system present during the catatonic phase in these cases.


Urinary Excretion Phenolic Acid Sympathetic Nervous System Active Phase Urinary Catecholamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armstrong, M. D., Shaw, K. N. F. and Wall, P. E. (1956): The phenolic acids in human urine. J. biol. Chem.218, 293–303.PubMedGoogle Scholar
  2. Bunney, W. E. Jr., Murphy, D. L., Goodwin, F. K. and Borge, G. (1970): The switch process from depression to mania: relationship to drugs which alter brain amines. Lancet1, 1022–1027.PubMedCrossRefGoogle Scholar
  3. Carlsson, A., Rasmussen, E. B. and Kristjansen, P. (1959): The urinary excretion of adrenaline and noradrenaline by schizophrenic patients during reserpine treatment. J. Neurochem.4, 318–320.PubMedCrossRefGoogle Scholar
  4. Gjessing, L. R. (1932): Beiträge zur Kenntnis der Pathophysiologie des katatonen Stupors: I. Mitteilung. Über periodisch rezidivierenden katatonen Stupor, mit kritischem Beginn und Abschluss. Arch. Psychiat. Nervenkr.96, 319–392.CrossRefGoogle Scholar
  5. Gjessing, L. R. (1935): Beiträge zur Kenntnis der Pathophysiologie der katatonen Erregung: III. Mitteilung. Über periodisch rezidivierende katatone Erregung, mit kritischem Beginn und Abschluss. Arch. Psychiat. Nervenkr.104, 355–416.CrossRefGoogle Scholar
  6. Gjessing, L. R. (1953): Beiträge zur Somatologie der periodischen Katatonie: VIII. Mitteilung. Wertung der Befunde II. Arch. Psychiat. Nervenkr.191, 297–326.PubMedCrossRefGoogle Scholar
  7. Gjessing, L. R. (1964a): Studies of periodic catatonia: I. Blood levels of protein-bound iodine and urinary excretion of vanillylmandelic acid in relation to clinical course. J. psychiat. Res.2, 123–134.CrossRefGoogle Scholar
  8. Gjessing, L. R. (1964b): Studies of periodic catatonia: II. The urinary excretion of phenolic amines and acids with and without loads of different drugs. J. psychiat. Res.2, 149–162.CrossRefGoogle Scholar
  9. Gjessing, L. R. (1965): Studies on urinary phenolic compounds in man. II. Phenolic acids and amines during a load of α-methyldopa and Disulfiram in periodic catatonia. Scand. J. clin. Lab. Invest.17, 549–557.PubMedCrossRefGoogle Scholar
  10. Gjessing, L. R. (1967a): Lithium citrate loading of a patient with periodic catatonia. Acta psychiat. scand.43, 372–375.PubMedCrossRefGoogle Scholar
  11. Gjessing, L. R. (1967b): Effect of thyroxine, pyridoxine, orphenadrine-HCl, reserpine and Disulfiram in periodic catatonia. Acta psychiat. scand.43, 376–384.PubMedCrossRefGoogle Scholar
  12. Greenspan, K., Schildkraut, J. J., Gorden, E. K., Baer, L., Aronoff, M. S. and Durell, J. (1970): Catecholamine metabolism in affective disorders — III. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J. psychiat. Res.7, 171–183.PubMedCrossRefGoogle Scholar
  13. Hatotani, N., Ishida, C., Yum, R., Maeda, M., Kato, Y., Nomura, Y., Wakao, T., Takekoshi, A., Yoshimoto, S., Yoshimoto, K. and Hiramoto, K. (1962): Psychophysiological studies of atypical psychosis — endocrinological aspect of periodic psychoses. Folia psychiat. neurol. jap.16, 248–292.Google Scholar
  14. Kakimoto, Y. and Armstrong, M. D. (1962): The phenolic amines of human urine. J. biol. Chem.237, 208–214.PubMedGoogle Scholar
  15. Paul, M. I., Cramer, H. and Bunney, W. E., Jr. (1971): Urinary adenosine 3’,5’-monophosphate in the switch process from depression to mania. Science171, 300–303.PubMedCrossRefGoogle Scholar
  16. Pllin, W. and Goldin, S. (1961): The physiological and psychological effects of intravenously administered epinephrine and its metabolism in normal and schizophrenic men— II. Psychiatric observations. J. psychiat. Bes.1, 50–67.CrossRefGoogle Scholar
  17. Pscheidt, G. R., Berlet, H. H., Bull, C., Spaide, J. and Himwich, H. E. (1964): Excretion of catecholamines and exacerbation of symptoms in schizophrenic patients. J. psychiat. Res.2, 163–168.CrossRefGoogle Scholar
  18. Schildkraut, J. J., Klerman, G. L., Hammond, R. and Friend, D. G. (1964): Excretion of 3-methoxy-4-hydroxy-mandelic acid (VMA) in depressed patients treated with antidepressant drugs. J. psychiat. Res.2, 257–266.CrossRefGoogle Scholar
  19. Takahashi, S. and Gjessing, L. R. (1972): Fluorometric method combined with thin-layer chromatography for the determination of epinephrine, norepinephrine and dopamine in human urine. (In preparation).Google Scholar
  20. Takahashi, S. and Gjessing, L. R.: Studies of periodic catatonia—IV. Longitudinal study of catecholamine metabolism, with and without drugs. J. psychiat. Res. (In press).Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 1973

Authors and Affiliations

  • S. Takahashi
    • 1
  • L. R. Gjessing
    • 1
  1. 1.Central LaboratoryDikemark HospitalSolbergNorway

Personalised recommendations